诺诚健华 (688428)
InnoCare Pharma Limited
K-Line Chart
No K-line data available
Company NameInnoCare Pharma Limited
Listing Date2022-09-21
Issue Price11.03RMB
Registered Capital176256.720210k RMB
Legal RepresentativeJisong Cui
Registered AddressOgier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands
IndustryChemical Pharmaceuticals
Main BusinessClinical-stage biopharmaceutical company
Company ProfileInnoCare Pharma Limited is an innovative biopharmaceutical company driven by exceptional in-house R&D capabilities, with comprehensive research, development, and commercialization capacities. It focuses on areas with significant unmet clinical needs, such as oncology and autoimmune diseases, developing best-in-class or first-in-class drugs with breakthrough potential in the global market.
Led by a management team with extensive experience in R&D, production, and commercialization, the company has built an integrated biopharmaceutical platform that balances research quality and speed. It has established a product pipeline with a high balance of innovation and risk, covering multiple highly promising hot targets, and is accelerating its growth to become a biopharmaceutical leader developing and providing innovative therapies for cancer and autoimmune disease patients worldwide. One of its key products, Orelabrutinib (Yinuokai?), received conditional approval from the National Medical Products Administration (NMPA) in December 2020. Tafasitamab has been approved for use as a clinically urgently needed imported drug at the Boao Super Hospital. Twelve products are in Phase I/II/III clinical trials, and four products are in the preclinical stage.
Stock Details
1. Key Indicators
- Total Shares(W): 176464.40
- Circulating A-Shares(W): 26835.97
- Earnings Per Share(RMB): -0.0200
- Net Assets Per Share(RMB): 3.8031
- Operating Revenue(W RMB): 73143.42
- Total Profit(W RMB): -3058.36
- **Net Profit Attributable to Parent(W RMB) **: -3009.14
- Net Profit Growth Rate(%): 88.51
- Weighted Return on Equity(%): -0.4500
- Operating Cash Flow Per Share(RMB): -0.0350
- Undistributed Profit Per Share(RMB): -3.1490
- Capital Reserve Per Share(RMB): 6.8901
2. Main Business
The main business covers:
- R&D, production and commercialization of innovative drugs
3. Company Basic Information
- Company Name: Innocare Pharma Limited
- Listing Date: 2022-09-21
- Industry: Pharmaceutical Manufacturing
- Address: Building 8, No. 8 Life Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing
- Website: https://www.Innocarepharma.com
- Company Profile: On November 3, 2015, the Cayman Islands Company Registry issued a "Certificate of Incorporation" to the company, which was registered and established in the Cayman Islands under the "Cayman Islands Companies Law". At the time of its establishment, the company had an authorized share capital of USD 50,000, a total authorized number of shares of 500,000,000, with an initial par value of USD 0.0001 per share.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Fullgoal Precision Medicine Flexible Allocation Hybrid Securities Investment Fund - Class A | Fund | 1215.49 | 4.53 |
| 2 | Ping An Healthcare Hybrid Securities Investment Fund - Class A | Fund | 862.66 | 3.21 |
| 3 | Wanjia Economic New Momentum Hybrid Securities Investment Fund - Class A | Fund | 600.00 | 2.24 |
| 4 | China Universal Healthcare Service Flexible Allocation Hybrid Securities Investment Fund - Class A | Fund | 545.10 | 2.03 |
| 5 | DONG Fang Hong Healthcare Upgrade Equity Initiated Securities Investment Fund - Class A | Fund | 458.94 | 1.71 |
| 6 | Bosera Healthcare Health Shanghai-Hong Kong-Shenzhen Equity Securities Investment Fund - Class A | Fund | 405.54 | 1.51 |
| 7 | China Universal Daxin Flexible Allocation Hybrid Securities Investment Fund - Class A | Fund | 398.15 | 1.48 |
| 8 | Fullgoal Healthcare Industry Hybrid Securities Investment Fund - Class A | Fund | 237.89 | 0.89 |
| 9 | CSC Financial Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund - Class A | Fund | 225.00 | 0.84 |
| 10 | Ping An Pharmaceutical Selection Equity Securities Investment Fund - Class A | Fund | 190.17 | 0.71 |
5. Concept Sectors
- H-Share
- Innovative Drug
- Margin Trading & Securities Lending
- Consecutive Losses
- Fund Reduction
- STAR Market Growth Layer
Remarks
- Data update date: 2025-11-05
- Data source: Public Market Information